Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Improved Treatment of MT-3 Breast Cancer and Brain Metastases in a Mouse Xenograft by LRP-Targeted Oxaliplatin Liposomes.

Orthmann A, Peiker L, Fichtner I, Hoffmann A, Hilger RA, Zeisig R.

J Biomed Nanotechnol. 2016 Jan;12(1):56-68.

PMID:
27301172
2.

Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis.

Roblek M, Calin M, Schlesinger M, Stan D, Zeisig R, Simionescu M, Bendas G, Borsig L.

J Control Release. 2015 Dec 28;220(Pt A):341-347. doi: 10.1016/j.jconrel.2015.10.055. Epub 2015 Oct 30.

3.

Inhibition of chemokine receptor CCR2 reduces sarcoma cell transendothelial migration and metastasis to the lungs.

Schlesinger M, Zeisig R, Ortmann K, Calin M, Gerber U, Roblek M, Borsig L, Bendas G.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1046-8. doi: 10.5414/CPXCES14EA04. No abstract available.

PMID:
26249764
4.

How perifosine affects liposome-encapsulated drug delivery across a cell barrier.

Testen A, Podlipec R, Mravljak J, Orthmann A, Šentjurc M, Zeisig R, Štrancar J, Koklic T.

Ther Deliv. 2015;6(4):423-41. doi: 10.4155/tde.14.127.

PMID:
25996042
5.

Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.

Kratz F, Azab S, Zeisig R, Fichtner I, Warnecke A.

Int J Pharm. 2013 Jan 30;441(1-2):499-506. doi: 10.1016/j.ijpharm.2012.11.003. Epub 2012 Nov 10.

PMID:
23149257
6.

Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.

Orthmann A, Zeisig R, Süss R, Lorenz D, Lemm M, Fichtner I.

Pharm Res. 2012 Jul;29(7):1949-59. doi: 10.1007/s11095-012-0723-7. Epub 2012 Mar 8.

PMID:
22399388
7.

Improving the transport of chemotherapeutic drugs across the blood-brain barrier.

Orthmann A, Fichtner I, Zeisig R.

Expert Rev Clin Pharmacol. 2011 Jul;4(4):477-90. doi: 10.1586/ecp.11.26. Review.

PMID:
22114857
8.

The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.

Schlesinger M, Schmitz P, Zeisig R, Naggi A, Torri G, Casu B, Bendas G.

Thromb Res. 2012 May;129(5):603-10. doi: 10.1016/j.thromres.2011.10.023. Epub 2011 Nov 17.

PMID:
22099706
9.

Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.

Abu Ajaj K, El-Abadla N, Welker P, Azab S, Zeisig R, Fichtner I, Kratz F.

Eur J Cancer. 2012 Sep;48(13):2054-65. doi: 10.1016/j.ejca.2011.08.003. Epub 2011 Sep 19.

PMID:
21937219
10.

Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.

Schlesinger M, Naggi A, Torri G, Zeisig R, Alexander M, Schmitz P, Casu B, Bendas G.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):448-50. No abstract available.

PMID:
20557840
11.

Determination of the amount of micelles in alkylphospholipid liposome formulations with electron paramagnetic resonance method.

Koklic T, Sentjurc M, Zeisig R.

J Liposome Res. 2011 Mar;21(1):1-8. doi: 10.3109/08982101003596133. Epub 2010 Mar 1.

PMID:
20192611
12.

Impact of membrane properties on uptake and transcytosis of colloidal nanocarriers across an epithelial cell barrier model.

Orthmann A, Zeisig R, Koklic T, Sentjurc M, Wiesner B, Lemm M, Fichtner I.

J Pharm Sci. 2010 May;99(5):2423-33. doi: 10.1002/jps.22001.

PMID:
20014431
13.

Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions.

Wenzel J, Zeisig R, Fichtner I.

Clin Exp Metastasis. 2010;27(1):25-34. doi: 10.1007/s10585-009-9299-y. Epub 2009 Nov 15.

PMID:
19916050
14.

Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.

Wenzel J, Zeisig R, Haider W, Habedank S, Fichtner I.

Breast Cancer Res Treat. 2010 May;121(1):13-22. doi: 10.1007/s10549-009-0448-4. Epub 2009 Jun 23.

PMID:
19548083
15.

Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.

Wenzel J, Zeisig R, Fichtner I.

Int J Pharm. 2009 Mar 31;370(1-2):121-8. doi: 10.1016/j.ijpharm.2008.11.023. Epub 2008 Dec 3.

PMID:
19100823
16.

Interaction of alkylphospholipid liposomes with MT-3 breast-cancer cells depends critically on cholesterol concentration.

Koklic T, Zeisig R, Sentjurc M.

Biochim Biophys Acta. 2008 Dec;1778(12):2682-9. doi: 10.1016/j.bbamem.2008.08.024. Epub 2008 Sep 12.

17.

Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice.

Zeisig R, Koklic T, Wiesner B, Fichtner I, Sentjurc M.

Arch Biochem Biophys. 2007 Mar 1;459(1):98-106. Epub 2006 Oct 18.

PMID:
17222386
18.

Membrane switch hypothesis. 1. Cell density influences lateral domain structure of tumor cell membranes.

Koklic T, Pirs M, Zeisig R, Abramović Z, Sentjurc M.

J Chem Inf Model. 2005 Nov-Dec;45(6):1701-7.

PMID:
16309276
19.

Synthesis and biological evaluation of spin-labeled alkylphospholipid analogs.

Mravljak J, Zeisig R, Pecar S.

J Med Chem. 2005 Oct 6;48(20):6393-9.

PMID:
16190765
20.

Effect of surface modified liposomes on the aggregation of platelets and tumor cells.

Keil C, Zeisig R, Fichtner I.

Thromb Haemost. 2005 Aug;94(2):404-11.

PMID:
16113832
21.

Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro.

Zeisig R, Teppke AD, Behrens D, Fichtner I.

Breast Cancer Res Treat. 2004 Oct;87(3):245-54.

PMID:
15528967
22.

Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo.

Zeisig R, Rückerl D, Fichtner I.

Anticancer Drugs. 2004 Aug;15(7):707-14.

PMID:
15269602
23.

In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.

Fichtner I, Becker M, Zeisig R, Sommer A.

Eur J Cancer. 2004 Apr;40(6):845-51. Review.

PMID:
15120040
24.

Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro.

Zeisig R, Stahn R, Wenzel K, Behrens D, Fichtner I.

Biochim Biophys Acta. 2004 Jan 28;1660(1-2):31-40.

25.

Animal experiments-an essential component for the development of liposomal anticancer agents.

Fichtner I, Reszka R, Arndt D, Zeisig R.

J Liposome Res. 2003 Feb;13(1):9-15. Review. No abstract available.

PMID:
12725721
26.

Lipoplexes with alkylphospholipid as new helper lipid for efficient in vitro and in vivo gene transfer in tumor therapy.

Zeisig R, Ress A, Fichtner I, Walther W.

Cancer Gene Ther. 2003 Apr;10(4):302-11.

PMID:
12679803
27.
28.

Inhibition of carbohydrate mediated cell adhesion by liposomes as a possible [correction of possibile] way to prevent tumour metastasis.

Zeisig R, Stahn R, Fichtner I.

Cell Mol Biol Lett. 2002;7(2):270-1. No abstract available.

PMID:
12097945
30.

Phospholipid- and fatty acid-composition in the erythrocyte membrane of the one-humped camel [Camelus dromedarius] and its influence on vesicle properties prepared from these lipids.

Warda M, Zeisig R.

Dtsch Tierarztl Wochenschr. 2000 Sep;107(9):368-73. Erratum in: Dtsch Tierarztl Wochenschr 2001 Jan;108(1):36.

PMID:
11471495
32.

Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice.

Arndt D, Zeisig R, Bechtel D, Fichtner I.

Drug Deliv. 2001 Jan-Mar;8(1):1-7.

PMID:
11280437
33.

Sialyl Lewis(x)-liposomes as vehicles for site-directed, E-selectin-mediated drug transfer into activated endothelial cells.

Stahn R, Grittner C, Zeisig R, Karsten U, Felix SB, Wenzel K.

Cell Mol Life Sci. 2001 Jan;58(1):141-7.

PMID:
11229813
34.

Cell adhesion inhibition by glycoliposomes: effects of vesicle diameter and ligand density.

Stahn R, Zeisig R.

Tumour Biol. 2000 May-Jun;21(3):176-86.

PMID:
10754468
36.
37.

Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.

Arndt D, Zeisig R, Eue I, Sternberg B, Fichtner I.

Breast Cancer Res Treat. 1997 May;43(3):237-46.

PMID:
9150903
38.
39.
40.
41.

Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells.

Eue I, Zeisig R, Arndt D.

J Cancer Res Clin Oncol. 1995;121(6):350-6.

PMID:
7797600
42.

Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells.

Zeisig R, Jungmann S, Fichtner I, Daemen T, Arndt D.

Anticancer Res. 1994 Sep-Oct;14(5A):1785-9.

PMID:
7847811
43.

Phospholipid analogues: side chain- and polar head group-dependent effects on phosphatidylcholine biosynthesis.

Geilen CC, Haase A, Wieder T, Arndt D, Zeisig R, Reutter W.

J Lipid Res. 1994 Apr;35(4):625-32.

44.

Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.

Fichtner I, Zeisig R, Naundorf H, Jungmann S, Arndt D, Asongwe G, Double JA, Bibby MC.

Breast Cancer Res Treat. 1994;32(3):269-79.

PMID:
7865855
45.

Antineoplastic activity in vitro of free and liposomal alkylphosphocholines.

Zeisig R, Jungmann S, Arndt D, Schütt A, Nissen E.

Anticancer Drugs. 1993 Feb;4(1):57-64.

PMID:
8457716
46.

Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.

Zeisig R, Fichtner I, Arndt D, Jungmann S.

Anticancer Drugs. 1991 Aug;2(4):411-7.

PMID:
1797199
47.

[Ether lipids--synthesis and application in tumor therapy].

Zeisig R, Arndt D, Brachwitz H.

Pharmazie. 1990 Nov;45(11):809-18. Review. German. No abstract available.

PMID:
2100332

Supplemental Content

Loading ...
Support Center